90 176

Cited 0 times in

신질환이 있는 경증 미치 중등도의 고혈압 환자에서 Irbesartan의 항고혈압효과 및 안전성을 평가하기 위한 제 4상 임상 시험

Other Titles
 Phase IV Study on the Antihypertensive Effect and Safety of Irbesartan in Patients with Mild to Moderate Hypertension and Renal Disease 
Authors
 윤수영  ;  한승혁  ;  박정엽  ;  송영수  ;  김병극  ;  김주성  ;  노현정  ;  노현진  ;  신석균  ;  최규헌  ;  한대석  ;  이호영 
Citation
 Korean Journal of Nephrology (대한신장학회지), Vol.19(4) : 731-739, 2000 
Journal Title
Korean Journal of Nephrology(대한신장학회지)
ISSN
 1225-0015 
Issue Date
2000
Keywords
Irbesartan ; Angiotnsin II receptor antagonist ; Hypertension ; Renal disease
Abstract
Irbesartan is a new selective angiotensin II subtype 1 receptor antagonist. We evaluated the efficacy and tolerability of irbesartan in patients with mild to moderate hypertension and renal disease. On 24 hypertensive patients, oral irbesartan 150mg a day was administered. In cases whose seated diastolic blood pressure did not decrease to 85mmHg after treatment for 4 weeks, the dose of irbesartan was increased to 300mg per day. Every 4 weeks, blood pressure, heart rates, and adverse effects were monitored. And we assessed WBC counts, hemoglobin, hematocrits, platelets, creatinine, BUN, total protein, albumin, fasting blood sugar, total cholesterol, AST, ALT, alkaline phosphatase, total bilirubin, sodium, potassium, calcium, uric acid and urine protein/creatinine ratio to evaluate the change of renal and hepatic function and other adverse effects. Seated systolic blood pressure was decreased from 157.1±3.1mmHg to 135.5±3.7mmHg, and seated diastolic blood pressure was also decreased frorn 99.2±1.7mmHg to 84.3±2.5mmHg. Irbesartan was effective in lowering blood pressure in 20 among 24 patients, and the effective rate of this drug was 83.3%. After treatment, a non clinically significant increase of heart rates and statistically significant decrease of total cholesterol level were noted. There was no dose-related adverse effect. We conclude that irbesartan is a safe and effective angiotensin II subtype 1 receptor antagonist for lowering blood pressure in patients with mild to moderate hyrtension and renal disease.
Files in This Item:
T200001547.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Choi, Kyu Hun(최규헌) ORCID logo https://orcid.org/0000-0003-0095-9011
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/172232
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links